<DOC>
	<DOCNO>NCT01041521</DOCNO>
	<brief_summary>The study seek determine use omega three fatty acid individual infect HIV high triglyceride lead improved triglyceride level , well blood vessel function decrease amount obstruction blood vessel .</brief_summary>
	<brief_title>The Impact Omega Three Fatty Acids Vascular Function HIV</brief_title>
	<detailed_description>While omega-three fatty acid show beneficial TG HDL-C level HIV uninfected individual small , short duration study HIV-infected individual , data extend observation determine whether intake omega-three fat prolong time period also beneficial impact functional outcome vascular endothelial function anatomic surrogate marker CVD HIV-infected patient . We propose randomize , double blind trial purify omega-three fatty acid HIV-infected individual elevate level triglyceride . While impact omega-three fatty acid lipid profile evident early ( within 12 week ) ; propose conduct trial full 24 month test overall hypothesis intervention improve triglyceride HDL-C level , improve HDL-subpopulations , plasma membrane phospholipid decrease inflammation , also improve brachial artery reactivity test ( BART ) measure vascular endothelial function 24 week 24 month arterial stiffness measure pulse wave velocity test surrogate marker CVD risk 24 month compare control . The specific aim proposal include : 1 . To conduct randomize , placebo control trial omega-three fatty acid 24 month HIV-infected individual elevate level triglyceride ( &gt; 150 mg/dl ) . 2 . To demonstrate impact omega-three fatty acid intake TG level HDL-C level , HDL subpopulation , composition plasma membrane phospholipid , chronic inflammation measure CRP , sPLA2 level arachidonic acid . 3 . To demonstrate impact omega-three fatty acid intake BART 24 week 24 month arterial stiffness 24 month .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>HIVinfected men woman least 18 year age , On stable HAART previous two month without anticipated change HAART regimen throughout duration study , Fasting triglycerides &gt; 150 mg/dl &lt; 2,500 mg/dl Participants may lipid lower therapy ; lipid lowering therapy , therapy must stable 8 week change course study . Participants may beta blocker ( e.g. , Atenolol , Metoprolol , Propranolol ) , Estrogens ( e.g. , Estinyl ; Estrace ; Estraderm ) , however therapy agent must stable 8 week start study alter study unless deem medically necessary participant 's medical provider approve Dr. Wanke . Female participant reproductive age must pregnant ( negative test ) lactate screen throughout trial agree use contraception course trial 2 month trial unless surgically sterilize ( tubal ligation hysterectomy ) , postmenopausal menses &gt; 1 year . Ability provide consent . plasma HIV1 RNA &gt; 10,000 copies/ml change HAART regimen two month prior study entry change lipid lower therapy within 2 month ( 8 week ) Pregnancy female participant Evidence liver renal disease value liver enzymes &gt; 5 X upper limit normal creatinine &gt; 1.5 X upper limit normal presence active opportunistic infection malignancy presence inflammatory end organ disease ( , rheumatoid arthritis , active treatment hepatitis c , disease may alter inflammatory marker ) routine ingestion fish oil ( individual use fish oil would reconsider study participation discontinue use fish oil 8 week TG level remain elevated ) . Allergic fish Lovaza BMI &gt; 35</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Elevated Triglyceride level</keyword>
	<keyword>vascular function ( BART )</keyword>
	<keyword>arterial stiffness</keyword>
	<keyword>omega three fatty acid</keyword>
	<keyword>complementary therapy</keyword>
</DOC>